As part of MHRP’s ongoing African Cohort Study (AFRICOS), researchers assessed the prevalence and incidence of HIV-TB among participants receiving services supported by the President’s Emergency Plan for AIDS Relief (PEPFAR) to identify factors associated with co-morbidity and better understand gaps in TB screening and diagnosis.
The 2023 Conference on Retroviruses and Opportunistic Infections (CROI) will kick off on February 19 in Seattle, Washington. Check out MHRP and collaborators at CROI.
MHRP’s African Cohort Study (AFRICOS), a multisite, long-term study that evaluates HIV prevention, care and treatment services it supports through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), is entering its ninth year in 2022. Over the past year, MHRP researchers and collaborators published 13 papers in peer-reviewed journals. A sampling of cohort research reveals the breadth of research conducted under AFRICOS:
The U.S. Embassy in Tanzania has recognized Dr. Hamada Shaban as a “Hero of the Fight Against COVID-19” for his contributions to the success of MHRP’s PEPFAR-funded vaccination campaign in the Southern Highlands region.
MHRP and collaborators recently launched a Phase 1 trial that will evaluate safety, tolerability, and immunogenicity of varying doses of the Army’s novel ALFQ adjuvant in a candidate HIV vaccine to optimize adjuvant dosage.
The Walter Reed Army Institute of Research (WRAIR) has conducted a first-in-human evaluation of a novel malaria vaccine candidate containing the FMP013 antigen and the ALFQ adjuvant, both developed at WRAIR. Results were published August 30 in the journal Vaccine.
